Login Register Cart 0
Generic placeholder image

Current Enzyme Inhibition

Editor-in-Chief

ISSN (Print): 1573-4080
ISSN (Online): 1875-6662

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Relationship with Metalloproteinase 13, E-cadherin, Homocysteine and Co Factors Folic Acid and Vitamin B12 in Patients Diagnosed with Prostate Cancer

Author(s): Thaís M. Gascón*, Beatriz G. Lourenço, Edimar C. Pereira, Beatriz A. da Costa Aguiar, Glaucia L. Veiga, Flavia de Sousa Gehrke, Fernando Adami and Fernando L.A. Fonseca

Volume 17, Issue 1, 2021

Published on: 26 October, 2020

Page: [33 - 41] Pages: 9

DOI: 10.2174/1573408016999201026195354

Price: $65

Abstract

Introduction: Prostate cancer (Pc) is the most frequent neoplasia in men and the second cause of death in Brazil.

Objective: To analyze the interactions and biologicals responses of Pc oxidative stress and prostatespecific antigen (PSA), E-cadherin and MMP-13. Demonstrate whether the increase of the amount of the form of E-cadherin found in the plasma of Pc patients, correlates with decrease of the PSA.

Methods: Samples were obtained through peripheral venipuncture to analyse parameters of biomarkers pc as PSA, E-cadherin, MMP-13, Homocysteine, Folic acid, Vitamin B12, Testosterone T and free following the patients diagnosis, 3 and 6 months during their treatment to analyze the biological responses of Pc oxidative stress.

Results: The analysis was performed by using immunoenzymatic assay. Statistical data processed through Excel in Windows Vista and analyzed through the Shapiro-wilk Test, ANOVA, and Spearman Test. An increase in the concentration of E-cadherin (p = 0.02), as a decrease in concentration of PSA (p < 0.001), total testosterone (p < 0.001) and free testosterone (p = 0.02) was observed during the treatment period without significant alterations in the remaining markers for either of the periods.

Discussion: It was found that during treatment of men diagnosed with pc that there was an an increase in the concentration of plasmatic E-cadherin, which was negatively correlated with the concentrations of folic acid (-0,03 (0,87) rs (p). It was observed that the levels of hcy are positively correlated with concentrations of total testosterone and a negative correlation. Vitamins B12 remained within the parameters of normality during the entire study.

Conclusion: P.S.A levels were free and total testosterone levels decreased. In this way, monitoring the folic acid, E-cadherin dosages of patients during the treatment phases can effectively complement in the face of remission, since it would be a way of preventing abnormal cell replications, with a clinical view prudent so that the cell methylation cycle is not affected.

Keywords: Prostate cancer, metalloproteinase-13, E-cadherin, homocysteine, biomarkers, prostate-specific antigen.

« Previous Next »
Graphical Abstract

[1]
Kowalczyk, A.P.; Nanes, B.A. Adherens junction turnover: regulating adhesion through cadherin endocytosis, degradation, and recycling. Subcell. Biochem., 2012, 60, 197-222.
[http://dx.doi.org/10.1007/978-94-007-4186-7_9] [PMID: 22674073]
[2]
Li, Y.; Tollefsbol, T.O. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr. Med. Chem., 2010, 17(20), 2141-2151.
[http://dx.doi.org/10.2174/092986710791299966] [PMID: 20423306]
[3]
INCA-Instituto Nacional de Câncer. 2018.http://www.inca.gov.br/estimativa/2018/referencias.asp
[4]
Paz, A.P.E.; Guimarães, M.R.; Muzi, D.C. Análise da tendência da mortalidade masculina no Rio de Janeiro: Contribuição da enfermagem. Esc Anna Nery.ed., 2014, 18(4), 593-599.
[5]
Walter, S.H.; Ahmed, S. Targeted therapies in cancer. Cancer Treatment. Surgery; Published by Elsevier Ltd, 2017, 36(3)
[6]
Oh, B.; Figtree, G.; Costa, D. Oxidative stress in prostate cancer patients: A systematic review of case control studies. Prostate Int., 2016, 4, 71-87.https://DOI.org/10.1016/j.prnil.2016.05.002
[http://dx.doi.org/10.1016/j.prnil.2016.05.002]
[7]
Stabler, S.; Koyama, T.; Zhao, Z.; Martinez-Ferrer, M.; Allen, R.H.; Luka, Z.; Loukachevitch, L.V.; Clark, P.E.; Wagner, C.; Bhowmick, N.A. Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One, 2011, 6(8)e22486
[http://dx.doi.org/10.1371/journal.pone.0022486] [PMID: 21853037]
[8]
Silva, T.C.; Jasiulionis, G.M. Relação entre estresse oxidativo, alterações epigenéticas e câncer., 2014, 66, 2317-6660.
[http://dx.doi.org/10.21800/S0009-67252014000100015]
[9]
Hultdin, J.; Van Guelpen, B.; Bergh, A.; Hallmans, G.; Stattin, P. Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: A prospective study. Int. J. Cancer, 2005, 113(5), 819-824.
[http://dx.doi.org/10.1002/ijc.20646] [PMID: 15499634]
[10]
Tonon, A. Prostate cancer: A literature review. Health Res Magazine, 2009, 2(3), 403-410.
[11]
Dini, L.I.; Koff, W.J. Profile of prostate cancer at the clinic hospital in Porto Alegre. Rev. Assoc. Med. Bras. (1992), 2006, 52(1), 28-31.
[http://dx.doi.org/10.1590/S0104-42302006000100018] [PMID: 16622535]
[12]
Kleer, C.G.; van Golen, K.L.; Braun, T.; Merajver, S.D. Persistent E-cadherin expression in inflammatory breast cancer. Mod. Pathol., 2001, 14(5), 458-464.
[http://dx.doi.org/10.1038/modpathol.3880334] [PMID: 11353057]
[13]
Wang, Z.R.; Chen, H.; Gao, S.S.; Qiu, H.; Li, H.W.; Sun, Z.L.; Wang, J.M. Implications of soluble E-cadherin level of antiviral treatment in patients with chronic hepatitis C virus infection. Int. Immunopharmacol., 2019.74105708
[http://dx.doi.org/10.1016/j.intimp.2019.105708] [PMID: 31254956]
[14]
Wong, M.H.S.; Fang, M.C.; Chuah, H.L. E-cadherin: Its dysregulation in carcinogenesis and clinical implications. Crit. Rev. Oncol. Hematol., 2018, 121, 11-22.https://DOI.org/10.1016/j.critrevonc.2017.11.010
[15]
Drivalos, A.; Chrisofos, M.; Efstathiou, E. Expression of α5-integrin, α7-integrin, Ε-cadherin, and N-cadherinin localized prostate cancer. Urologic Oncology: Seminarsand Original Investigations, 2016, 165, e11-165-e18,34.
[16]
Padmanaban, V.; Krol, I.; Suhail, Y. E-cadherin is required for metastasis in multiple models of breast cancer. Nature, 2019, 573(7774), 439-444.
[17]
Kim, N.H.; Kim, S.N.; Kim, Y.K. Involvement of HDAC1 in E-cadherin expression in prostate cancer cells; its implication for cell motility and invasion. Biochem. Biophys. Res. Commun., 2011, 404(4), 915-921.
[http://dx.doi.org/10.1016/j.bbrc.2010.12.081] [PMID: 21184735]
[18]
Brasileiro Filho, G. Growth disorders and cell differentiation. In: Bogliolo pathology. Rio de Janeiro, Guanabara Koogan, 7th ed; , 2006; pp. 181-204.
[19]
Egeblad, M. Egeblad M: The role of metrix metalloproteinase 13 in breast cancer. Postdoctoral Fellowship (Cycle VII); Unversity of California, San Francisco, 2002.
[20]
Rodríguez, D.; Morrison, C.J.; Overall, C.M. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim. Biophys. Acta, 2010, 1803(1), 39-54.
[http://dx.doi.org/10.1016/j.bbamcr.2009.09.015] [PMID: 19800373]
[21]
Gascón, M.T.; Schindler, F. Avaliação do Método de Quimioluminescência na análise de homocisteína plasmática e sua comparação com o método de HPLC em amostras de crianças; Revista Einstein, 2010.
[22]
Cambruzzi, E.; Zettler, G.C.; Pegas, L.K. Relação entre escore de Gleason e fatores prognósticos no adenocarcinoma acinar de próstata. Bras. Patol. Med. Lab., 2010, 46(1), 61-68.
[http://dx.doi.org/10.1590/S1676-24442010000100011]
[23]
Diretrizes Diagnósticas e Terapêuticas do Adenocarcinoma de Próstata. Relatório de Recomendação., http://conitec.gov.br/2018
[24]
Reis, B.R.; Cassini, F.M. Antígeno Prostático Específico (P.S.A). Urologia fundamental. Cap., 2010, 2, 190-194.
[25]
Giltay, E.J.; Hoogeveen, E.K.; Elbers, J.M.; Gooren, L.J.; Asscheman, H.; Stehouwer, C.D. Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. J. Clin. Endocrinol. Metab., 1998, 83(2), 550-553.
[http://dx.doi.org/10.1210/jcem.83.2.4574] [PMID: 9467573]
[26]
Claps, M.; Petrelli, F.; Caffo, O.; Amoroso, V.; Roca, E.; Mosca, A.; Maines, F.; Barni, S.; Berruti, A. Testosterone levels and prostate cancer prognosis: Systematic review and meta-analysis. Clin. Genitourin. Cancer, 2018, 16(3), 165-175.e2.
[http://dx.doi.org/10.1016/j.clgc.2018.01.005] [http://dx.doi.org/10.1016/j.clgc.2018.01.005] [PMID: 29454638]
[27]
Collin, S.M.; Metcalfe, C.; Refsum, H.; Lewis, S.J.; Smith, G.D.; Cox, A.; Davis, M.; Marsden, G.; Johnston, C.; Lane, J.A.; Donovan, J.L.; Neal, D.E.; Hamdy, F.C.; Smith, A.D.; Martin, R.M. Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with prostate-specific antigen velocity in men with localized prostate cancer. Cancer Epidemiol. Biomarkers Prev., 2010, 19(11), 2833-2838.
[http://dx.doi.org/10.1158/1055-9965.EPI-10-0582] [PMID: 20852008]
[28]
Keshteli, H.A.; Baracos, V.; Madsen, K. Hyperhomocysteinemia as a potential contributor of colorectal cancer development in inflammatory bowel diseases: A review. World J. Gastroenterol., 2015, 21(4), 1081-1090.
[http://dx.doi.org/10.3748/wjg.v21.i4.1081]
[29]
Martínez-Poveda, B.; Chavarría, T.; Sánchez-Jiménez, F.; Quesada, A.R.; Medina, M.A. An in vitro evaluation of the effects of homocysteine thiolactone on key steps of angiogenesis and tumor invasion. Biochem. Biophys. Res. Commun., 2003, 311(3), 649-653.
[http://dx.doi.org/10.1016/j.bbrc.2003.10.044] [PMID: 14623320]
[30]
Mariano, C.; Steluti, J.; Marchioni, L, M. The vitamins and minerals related to genomic stability and cancer protection. Nutrire: rev. Soc. Bras. Alim. Nutr. J. Brazilian Soc. Food Nutr., São Paulo, SP, 2010, 35(2), 181-199.
[31]
Bonaldi, C.M.; Azzalis, L.A.; Junqueira, V.B.; de Oliveira, C.G.; Vilas Boas, V.A.; Gáscon, T.M.; Gehrke, F.S.; Kuniyoshi, R.K.; Alves, B.C.; Fonseca, F.L. Plasma levels of E-cadherin and MMP-13 in prostate cancer patients: correlation with PSA, testosterone and pathological parameters. Tumori, 2015, 101(2), 185-188.
[http://dx.doi.org/10.5301/tj.5000237] [PMID: 25733385]

Rights & Permissions Print Cite
Article Metrics
17
1
© 2024 Bentham Science Publishers | Privacy Policy